Ep. 219 GU ASCO Highlights: Key Takeaways for Clinicians with Dr. Ben Maughan and Dr. Shilpa Gupta

Do you need a recap of the latest urologic oncology research presented at GU ASCO 2025? This episode of BackTable Urology features a multidisciplinary discussion among three leading voices in urology and medical oncology – Drs. Bogdana Schmidt, Shilpa Gupta, and Ben Maughan – covering the most notable results presented at this year’s meeting. --- This podcast is supported by: Photocure https://www.photocure.com/ --- SYNPOSIS First, the doctors cover a wide range of topics including PARP inhibitors for prostate cancer, HER2-targeting antibody drug conjugates in bladder cancer, adjuvant chemotherapy for upper tract urothelial carcinoma, and biomarkers such as KIM-1 in kidney cancer. Highlighting the importance of multidisciplinary collaboration, the experts also critique the COSMIC-313 trial and discuss the nuances of applying new therapeutic combinations in real-world clinical practice. --- TIMESTAMPS 00:00 - Introduction 09:20 - TALAPRO-2 Trial Insights 19:29 - Bladder Cancer: Immuno-Oncology Combinations and HER2 27:42 - NIAGARA and iNDUCT Trials 33:32 - Future Directions in Upper Tract Treatment 37:38 - Biomarkers in Kidney Cancer: KIM-1 46:43 - COSMIC-313: Triplet Therapy in Renal Cell Carcinoma 52:39 - Concluding Thoughts and Future Directions --- RESOURCES Photocure: https://www.photocure.com/

There are no comments yet.

Please log in to write the first comment.